Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 14;10(4):e26193.
doi: 10.1016/j.heliyon.2024.e26193. eCollection 2024 Feb 29.

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal

Rasoul Hoseinpour  1   2   3 , Alka Hasani  2   4   5 , Behzad Baradaran  2 , Jalal Abdolalizadeh  6 , Roya Salehi  6 , Akbar Hasani  7 , Edris Nabizadeh  1   2 , Mina Yekani  8   9 , Roqaiyeh Hasani  10 , Hossein Samadi Kafil  4   6 , Khalil Azizian  11 , Mohammad Yousef Memar  1
Affiliations
Review

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal

Rasoul Hoseinpour et al. Heliyon. .

Abstract

Despite the widespread use of the Bacillus Calmette-Guérin (BCG) vaccine, Mycobacterium tuberculosis (MTB) continues to be a global burden. Vaccination has been proposed to prevent and treat tuberculosis (TB) infection, and several of them are in different phases of clinical trials. Though vaccine production is in progress but requires more attention. There are several TB vaccines in the trial phase, most of which are based on a combination of proteins/adjuvants or recombinant viral vectors used for selected MTB antigens. In this review, we attempted to discuss different types of TB vaccines based on the vaccine composition, the immune responses generated, and their clinical trial phases. Furthermore, we have briefly overviewed the effective delivery systems used for the TB vaccine and their effectiveness in different vaccines.

Keywords: Bacillus Calmette–Guérin; Delivery systems; Tuberculosis; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Types of tuberculosis vaccines based on composition.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ottenhoff T.H., Kaufmann S.H. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog. 2012;8(5) - PMC - PubMed
    1. Dalmia N., Ramsay A.J. Prime–boost approaches to tuberculosis vaccine development. Expet Rev. Vaccine. 2012;11(10):1221–1233. - PMC - PubMed
    1. Bagcchi S. WHO's global tuberculosis report 2022. The Lancet Microbe. 2023;4(1) - PubMed
    1. Kaufmann S.H. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity. 2010;33(4):567–577. - PubMed
    1. Ahsan M.J. Recent advances in the development of vaccines for tuberculosis. Therapeutic advances in vaccines. 2015;3(3):66–75. - PMC - PubMed

LinkOut - more resources